A new dosage schedule for pimozide in the acute stabilisation and maintenance treatment of psychosis.
In the present study, the value of pimozide, rapidly instituted at an optimal maintenance dose, for facilitating the social re-integration was assessed in 24 psychotic, mainly newly admitted, patients. The study comprised three stages spread over about 2 months, in which an optimal daily dose was individually fixed during stage 2 and maintained during stage 3. At the selection and at the end of stage 1, 2 and 3 (or at discharge) the psychiatric status of the patients was evaluated by means of the "Brief Psychiatric Rating Scale" and the resocialization readiness by means of the "Discharge Readiness Questionnaire". At completion of the trial 16 patients were ready for discharge.
D000328:Adult; D003909:Dexetimide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy*; D010868:Pimozide / Q000008:administration & dosage* / Q000009:adverse effects; D012559:Schizophrenia / Q000188:drug therapy*; D014202:Tremor / Q000139:chemically induced
D010868:Pimozide; D003909:Dexetimide; D006220:Haloperidol